Tao Zhao1, XiaoHou Wu2, JiaJi Liu1. 1. YongChuan Hospital, Department of Urology, Chongqing Medical University, YongChuan, Chongqing, China. 2. The First Affiliated Hospital of Chongqing, Department of Urology, Medical University, Chongqing, China.
Abstract
OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays. RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer. CONCLUSION: To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding.
OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays. RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer. CONCLUSION: To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding.
Authors: Rayjean J Hung; Paolo Boffetta; Paul Brennan; Christian Malaveille; Agnès Hautefeuille; Francesco Donato; Umberto Gelatti; Massimiliano Spaliviero; Donatella Placidi; Angela Carta; Antonio Scotto di Carlo; Stefano Porru Journal: Int J Cancer Date: 2004-07-01 Impact factor: 7.396
Authors: Branwen J Hennig; Angela J Frodsham; Simon Hellier; Susanne Knapp; Leland J Yee; Mark Wright; Lyna Zhang; Howard C Thomas; Mark Thursz; Adrian V Hill Journal: Liver Int Date: 2007-10 Impact factor: 5.828
Authors: Nadezda Lipunova; Anke Wesselius; Kar K Cheng; Frederik J van Schooten; Jean-Baptiste Cazier; Richard T Bryan; Maurice P Zeegers Journal: Biomark Cancer Date: 2019-12-30
Authors: Nada H Aljarba; Mashael R Al-Anazi; Mohammed I Shafeai; Fuad H Rudiny; Saad M Bin Dajem; Hani Alothaid; Majid Darraj; Saad Alkahtani; Jahad Alghamdi; Mohammed N Al-Ahdal; Ahmed A Al-Qahtani Journal: Mediators Inflamm Date: 2020-02-19 Impact factor: 4.711